Tom 13, Nr 5 (2016)
Nefrokardiologia
Opublikowany online: 2017-01-06
Wyświetlenia strony
678
Wyświetlenia/pobrania artykułu
3310
Ultrafiltracja w zaostrzeniach niewydolności serca — leczenie alternatywne czy terapia ostatniej szansy?
Choroby Serca i Naczyń 2016;13(5):367-377.
Streszczenie
Podstawową metodą leczenia przewodnienia wynikającego z zaostrzenia przewlekłej niewydolności serca (CHF) lub ostrej niewydolności serca (AHF) jest stosowanie leków moczopędnych. Istnieją sytuacje kliniczne, w których ta standardowa metoda jest nieskuteczna lub prowadzi do istotnych powikłań ograniczających jej przydatność. Oporność na diuretyki (OND) znacznie pogarsza rokowanie u pacjentów z epizodami zaostrzenia niewydolności serca (HF). Ultrafiltracja prowadzona za pomocą technik zewnątrzustrojowych (UZ) lub dializy otrzewnowej (DO), stosowana powszechnie u pacjentów w schyłkowym stadium przewlekłej choroby nerek (CKD), może się okazać bezpieczną i skuteczną metodą w leczeniu przewodnienia opornego na diuretyki i tym samym poprawić rokowanie w tej grupie pacjentów. Publikacja ma na celu omówienie metod ultrafiltracji (UF), które można zastosować w przypadku wystąpienia oporności na terapię konwencjonalną u pacjentów z CHF lub AHF.
Słowa kluczowe: przewlekła niewydolność sercaoporność na diuretykiultrafiltracja
Referencje
- Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014; 4(3-4): 176–188.
- Olszowska A, Próchnicka A, Żelichowski G, et al. Ultrafiltracja jako alternatywna metoda leczenia zastoinowej niewydolności serca opornej na diuretyki. Nefrol Dial Pol. 2010; 14: 77–80.
- Baczyński D, Wańkowicz Z. Dializa otrzewnowa w niewydolności serca. Problemy Lekarskie. 2006; 45: 171.
- Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119(14): 1977–2016.
- Gellert R, Daniewska D, Kobus D. Akwafereza w leczeniu zaostrzenia przewlekłej niewydolności serca — uzasadnienie i początkowe doświadczenia kliniczne jednego ośrodka. . Post Nauk Med. 2011; 6: 523–528.
- Courivaud C, Kazory A, Crépin T, et al. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014; 34(1): 100–108.
- Adams KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149(2): 209–216.
- Neuberg GW, Miller AB, O'Connor CM, et al. PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002; 144(1): 31–38.
- Buglioni A, Burnett JC. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta. 2015; 443: 3–8.
- Abassi ZA, Brodsky S, Karram T, et al. Temporal changes in natriuretic and antinatriuretic systems after closure of a large arteriovenous fistula. Cardiovasc Res. 2001; 51(3): 567–576.
- Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009; 4(12): 2013–2026.
- Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis. Heart Fail Rev. 2012; 17(2): 313–324.
- Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012; 5(1): 54–62.
- Beutler KT, Masilamani S, Turban S, et al. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension. 2003; 41(5): 1143–1150.
- Ecelbarger CA, Kim GH, Terris J, et al. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol. 2000; 279(1): F46–F53.
- Blazer-Yost BL, Liu X, Helman SI. Hormonal regulation of ENaCs: insulin and aldosterone. Am J Physiol. 1998; 274(5 Pt 1): C1373–C1379.
- Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994; 23(6): 1410–1420.
- Newton GE, Parker JD. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996; 94(3): 353–358.
- Navas JP, Martinez-Maldonado M. Pathophysiology of edema in congestive heart failure. Heart Dis Stroke. 1993; 2(4): 325–329.
- Rasool A, Palevsky PM. Treatment of edematous disorders with diuretics. Am J Med Sci. 2000; 319(1): 25–37.
- Chaney E, Shaw A. Pathophysiology of fluid retention in heart failure. Contrib Nephrol. 2010; 164: 46–53.
- Shin JT, Dec GW. Ultrafiltration should not replace diuretics for the initial treatment of acute decompensated heart failure. Circ Heart Fail. 2009; 2(5): 505–511.
- De Vecchis R, Baldi C. Cardiorenal syndrome type 2: from diagnosis to optimal management. Ther Clin Risk Manag. 2014; 10: 949–961.
- Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19): 1527–1539.
- Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008; 36(1 Suppl): S75–S88.
- Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med. 2008; 34(5): 957–962.
- Ronco C, McCullough P, Anker SD, et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010; 31(6): 703–711.
- Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002; 8(3): 136–141.
- Newsome BB, Warnock DG, McClellan WM, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008; 168(6): 609–616.
- Krumholz HM, Chen Y. Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol. 2000; 85: 1110–1113.
- Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005; 150(2): 330–337.
- Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003; 9(1): 13–25.
- Bhatia RS, Tu V, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 113: 671–678.
- Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol. 2009; 5(5): 287–296.
- Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003; 42(5): 1050–1065.
- Cannon PJ, Cannon PJ. The kidney in heart failure. N Engl J Med. 1977; 296(1): 26–32.
- Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008; 51(13): 1268–1274.
- Laederach K, Weidmann P. Plasma and urinary catecholamines as related to renal function in man. Kidney Int. 1987; 31(1): 107–111.
- Sah B, Graves K. The cardiorenal syndrome: a reviev. Int J Nephrol. 2011; 10: 1.
- Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994; 74(6): 1141–1148.
- Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003; 41(12): 2164–2171.
- Vaziri ND, Dicus M, Ho ND, et al. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003; 63(1): 179–185.
- Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000; 20(3): 645–651.
- Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol. 1931; 72(1): 49–61.
- Jie KE, Verhaar MC, Cramer MJM, et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006; 291(5): F932–F944.
- Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010; 121(23): 2592–2600.
- Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003; 100(8): 4802–4806.
- Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004; 19(2): 348–355.
- Kamath SA. The role of ultrafiltration in patients with decompensated heart failure. Int J Nephrol. 2010; 2011: 190230.
- Gellert R. Leczenie niewydolności serca ultrafiltracją. Forum Nefrol. 2014; 7: 12–16.
- Bruyne LDe. Mechanisms and management of diuretic resistance in congestive heart failure. Postgraduate Medical Journal. 2003; 79(>931): 268–271.
- Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994; 96(3): 191–199.
- Giglioli C, Landi D, Cecchi E, et al. Effects of ULTRAfiltration vs. DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study. Eur J Heart Fail. 2011; 13(3): 337–346.
- Snopek G, Kotlarska J, Daniewska D, et al. Zastosowanie ultrafiltracji żylnej w leczeniu chorych z ciężką, oporną na leczenie zastoinową niewydolnością serca — opis sześciu przypadków. Kardiol Pol. 2008; 66: 1202–1204.
- Jaski BE, Ha J, Denys BG, et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003; 9(3): 227–231.
- Rossi GP, Calò LA, Maiolino G, et al. Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart. Nephrol Dial Transplant. 2014; 29(7): 1335–1341.
- Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005; 46(11): 2047–2051.
- Radzishevsky E, Salman N, Paz H, et al. First experience in ambulatory ultrafiltration therapy for congested heart failure patients in Israel: a feasibility study. Isr Med Assoc J. 2015; 17(1): 24–26.
- Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005; 46(11): 2043–2046.
- Costanzo MR, Guglin ME, Saltzberg MT, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(6): 675–683.
- Bart BA, Goldsmith SR, Lee KL, et al. Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012; 367(24): 2296–2304.
- Ebrahim B, Sindhura K, Okoroh J, et al. Meta-Analysis of Ultrafiltration versus Diuretics Treatment Option for Overload Volume Reduction in Patients with Acute Decompensated Heart Failure. Arq Bras Cardiol. 2015; 104(5): 417–425.
- François K, Ronco C, Bargman JM. Peritoneal Dialysis for Chronic Congestive Heart Failure. Blood Purif. 2015; 40(1): 45–52.
- SCHNEIERSON SJ. Continuous peritoneal irrigation in the treatment of intractable edema of cardiac origin. Am J Med Sci. 1949; 218(1): 76–79.
- Rae AI, Hopper J. Removal of refractory oedema fluid by peritoneal dialysis. Br J Urol. 1968; 40(3): 336–343.
- Cnossen TT, Kooman JP, Krepel HP, et al. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant. 2012; 27(7): 2794–2799.
- Koch M, Haastert B, Kohnle M, et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012; 14(5): 530–539.
- Núñez J, González M, Miñana G, et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail. 2012; 14(5): 540–548.
- Cnossen TT, Kooman JP, Konings CJ, et al. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif. 2010; 30(2): 146–152.
- Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int. 2014; 34(1): 64–70.
- Sánchez JE, Ortega T, Rodríguez C, et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant. 2010; 25(2): 605–610.
- Lu R, Muciño-Bermejo MJ, Ribeiro LC, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med. 2015; 5(2): 145–156.
- Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int. 2014; 34(1): 64–70.
